Metabolomics and Lipidomics Signatures of Insulin Resistance and Abdominal Fat Depots in People Living with Obesity
Overview
Authors
Affiliations
The liver, skeletal muscle, and adipose tissue are major insulin target tissues and key players in glucose homeostasis. We and others have described diverse insulin resistance (IR) phenotypes in people at risk of developing type 2 diabetes. It is postulated that identifying the IR phenotype in a patient may guide the treatment or the prevention strategy for better health outcomes in populations at risk. Here, we performed plasma metabolomics and lipidomics in a cohort of men and women living with obesity not complicated by diabetes (mean [SD] BMI 36.0 [4.5] kg/m2, n = 62) to identify plasma signatures of metabolites and lipids that align with phenotypes of IR (muscle, liver, or adipose tissue) and abdominal fat depots. We used 2-step hyperinsulinemic-euglycemic clamp with deuterated glucose, oral glucose tolerance test, dual-energy X-ray absorptiometry and abdominal magnetic resonance imaging to assess muscle-, liver- and adipose tissue- IR, beta cell function, body composition, abdominal fat distribution and liver fat, respectively. Spearman’s rank correlation analyses that passed the Benjamini−Hochberg statistical correction revealed that cytidine, gamma-aminobutyric acid, anandamide, and citrate corresponded uniquely with muscle IR, tryptophan, cAMP and phosphocholine corresponded uniquely with liver IR and phenylpyruvate and hydroxy-isocaproic acid corresponded uniquely with adipose tissue IR (p < 7.2 × 10−4). Plasma cholesteryl sulfate (p = 0.00029) and guanidinoacetic acid (p = 0.0001) differentiated between visceral and subcutaneous adiposity, while homogentisate correlated uniquely with liver fat (p = 0.00035). Our findings may help identify diverse insulin resistance and adiposity phenotypes and enable targeted treatments in people living with obesity.
Hepatic Steatosis and Fibrosis, Cardiorespiratory Fitness, and Metabolic Mediators in the Community.
Florea V, Gajjar P, Huang S, Tang J, Zhao S, Davenport M Liver Int. 2024; 45(1):e16147.
PMID: 39673712 PMC: 11649011. DOI: 10.1111/liv.16147.
Amouzegar A, Honarvar M, Masoumi S, Agahi S, Azizi F, Mehran L BMJ Open. 2024; 14(9):e078701.
PMID: 39260837 PMC: 11409262. DOI: 10.1136/bmjopen-2023-078701.
Clinical metabolomics: Useful insights, perspectives and challenges.
Dalamaga M Metabol Open. 2024; 22:100290.
PMID: 39011161 PMC: 11247213. DOI: 10.1016/j.metop.2024.100290.
Duft R, Bonfante I, Palma-Duran S, Chacon-Mikahil M, Griffin J, Cavaglieri C J Clin Endocrinol Metab. 2024; 109(9):2182-2198.
PMID: 38488044 PMC: 11318996. DOI: 10.1210/clinem/dgae177.
Tian M, Ma X, Tong L, Jia L, Ding W Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(1):54-61.
PMID: 38269460 PMC: 10817734. DOI: 10.7499/j.issn.1008-8830.2306049.